Matthew E. Korenberg - 05 May 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
EVP,Finance & Strategy and CFO
Signature
By: Charles S. Berkman For: Matthew E. Korenberg
Issuer symbol
LGND
Transactions as of
05 May 2022
Net transactions value
$0
Form type
4
Filing time
09 May 2022, 20:10:30 UTC
Previous filing
16 Feb 2022
Next filing
14 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Award $0 +30,189 $0.000000 30,189 05 May 2022 Common Stock 30,189 $90.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 3-year, 9-month period measured from the date of grant, 12-1/2% after three months, then 1/48th of the Option Shares per month thereafter. The date of grant is 05/05/2022.